Assessing the cost-effectiveness of finding cases of hepatitis C infection in UK migrant populations and the value of further research

Journal of Viral Hepatitis

Volumn 21, Issue 9, 2014, Pages 616-623

  Miners, A H ^a   Martin, N K ^b   Ghosh, A ^c   Hickman, M ^b   Vickerman, P ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c London and Kent Surrey and Sussex Deanery   (United Kingdom)

Author keywords

case finding and migrants; economic evaluation; hepatitis C

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; TELAPREVIR; VIRUS RNA;

ANTIVIRAL THERAPY; ARTICLE; CASE FINDING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MIGRANT; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SEROPREVALENCE; SYSTEMATIC REVIEW (TOPIC); UNITED KINGDOM; COST BENEFIT ANALYSIS; DIAGNOSTIC PROCEDURE; ECONOMICS; PROCEDURES;

CLINICAL LABORATORY TECHNIQUES; COST-BENEFIT ANALYSIS; EMIGRANTS AND IMMIGRANTS; GREAT BRITAIN; HEPATITIS C; HUMANS;

EID: 84905489130     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12190     Document Type: Article

References (36)

1. World Health Organisation. Hepatitis C Fact sheet N°164. 2012. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/index.html. (accessed 3 June 2013).
2. Uddin G, Shoeb D, Solaiman S, et al,. Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: the prevalence cannot necessarily be predicted from the prevalence in the country of origin. J Viral Hepatitis 2010; 17: 327-335.
3. Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N,. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess, 2007; 11 (11).
4. Wright M, Grieve R, Roberts J, Main J, Thomas HC,. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006; 10 (21): 1-113.
5. Sroczynski G, Esteban E, Conrads-Frank A, et al,. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. J Viral Hepatitis 2010; 17 (1): 34-50.
6. Rosen HR,. Chronic Hepatitis C Infection. N Engl J Med 2011; 364: 2429-2438.
7. Health Protection Agency. Sentinel Surveillance of Hepatitis Testing in England-Hepatitis C testing 2010 Report-Analyses of HCV testing data between 2007 and 2010 Health. Colindale, UK: Health Protection Services, 2011.
8. Allaby M,. Screening for Hepatitis B and Hepatitis C among ethnic minorities born outside the UK: a report for the National Screening Committee. London: Solutions for Public Health, 2010.
9. National Screening Committee. Screening for Hepatitis B and Hepatitis C among ethnic minorities born outside the UK Policy Position Statement, London: National Screening Committee, 2011.
10. National Institute for Health and Clinical Excellence. Hepatitis B and C-ways to promote and offer testing. 2012. Available at: http://publications. nice.org.uk/hepatitis-b-and-c-ways-to-promote-and-offer-testing-to-people-at- increased-risk-of-infection-ph43. (accessed 3 June 2013).
11. Claxton K, Ginnelly L, Sculpher MJ, Philips Z, Palmer S,. A pilot study on the use of decision theory and value of information analysis as part of the National Health Service Health Technology Assessment Programme. Health Technol Assess 2004; 8 (31): 1-118.
12. Briggs A, Sculpher M, Claxton K,. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press, 2006.
13. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal. London: National Institute for Health and Care Excellence, 2013.
14. Beck JR, Pauker SG,. The Markov process in medical prognosis. Med Decis Making 1983; 3 (4): 419-458.
15. McPherson S, Valappil M, Moses S, et al,. CHASE-B (Chinese hepatitis awareness, surveillance, and education): a pilot of targeted case finding for hepatitis B virus (HBV) in the British-Chinese community. Gut, 2010; 60: A25-A26.
16. Lewis H, Burke K, Begum S, Ushiro-Limb I, Foster GR,. What is the best method of case finding for chronic viral hepatitis in migrant communities? Gut 2011; 60 (Suppl 2): A26.
17. Jafferbhoy H, Miller M, McIntyre P, Mcleod S, Dillon JF,. Outreach community testing for hepatitis C in an ethnic population. Gut 2010; 59: A13.
18. Jones L, Bates G, McCoy E, Beynon C, McVeigh J, Bellis M,. A systematic review of the effectiveness & cost-effectiveness of interventions aimed at raising awareness and engaging with groups who are at an increased risk of hepatitis B and C infection. 2011; Available at: http://www.nice.org.uk/ nicemedia/live/11957/59546/59546.pdf. (accessed 7 May 2013).
19. Office for National Statistics. Population by Country of birth and Nationality July 2010 to June 2011. 2012; Available at: http://www.ons.gov.uk/ ons/publications/re-reference-tables.html?edition=tcm%3A77-256033. (accessed 7 May 2013).
20. Office for National Statistics. 3.04 IPS Country of Birth by Sex, 1975-2011. 2011; Available at: http://www.ons.gov.uk/ons/publications/re- reference-tables.html?edition=tcm%3A77-280889. (accessed 7 May 2013).
21. Martin N, Vickerman P, Miners A, et al,. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology, 2012; 55 (1): 49-57.
22. Irving WL, Smith S, Cater R, et al,. Clinical pathways for patients with newly diagnosed hepatitis C-what actually happens. J Viral Hepatitis 2006; 13 (4): 264-271.
23. Micallef J, Kaldor J, Dore G,. Spontaneous viral clearance following hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepatitis 2006; 13: 34-41.
24. Hadziyannis SJ, Sette JH, Morgan TR, et al,. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140 (5): 346-355.
25. McHutchison JG, Lawitz EJ, Shiffman ML, et al,. Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. N Engl J Med 2009; 361 (6): 580-593.
26. Shiffman ML, Suter F, Bacon BR, et al,. Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3. N Engl J Med 2007; 357 (2): 124-134.
27. National Institute for Health and Clinical Excellence. Peginterferon Alfa and Ribavirin for the Treatment of Mild Chronic Hepatitis C. London: National Institute for Health and Clinical Excellence, 2006.
28. Bruno S, Shiffman ML, Roberts SK, et al,. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 2010; 51 (2): 388-397.
29. Martin N, Miners A, Vickerman P,. Assessing the Cost-Effectiveness of Interventions to Increase Hepatitis C Testing Among Injecting Drug Users: An Economic Modeling Report. London: London School of Hygiene and Tropical Medicine and University of Bristol, 2012. Available at: http://www.nice.org.uk/guidance/ index.jsp?action=download&o=59552 (accessed 2 August 2013)
30. Ratcliffe J, Longworth L, Young T, Bryan S, Burroughs A, Buxton M,. Assessing health-related quality of life pre- and post-liver transplantation: a prospective multicenter study. Liver Transpl 2002; 8 (3): 263-270.
31. Curtis L,. Unit costs of health & social care 2011, Personal Social Services Research Unit. University of Kent.
32. Shepherd J, Jones J, Takeda A, Davidson P, Price A,. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess, 2006; 10 (28).
33. Dakin H, Bentley A, Dusheiko G,. Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Value in Health 2010; 13: 922-923.
34. Thompson Coon J, Castelnuovoa E, Pitt M, Cramp M, Siebert U, Stein K,. Case finding for hepatitis C in primary care: a cost utility analysis. Fam Pract 2006; 23 (4): 393-406.
35. Veldhuijzen IK, Toy M, Hahné SJM, et al,. Screening and Early Treatment of Migrants for Chronic Hepatitis B Virus Infection Is Cost-Effective. Gastroenterology 2010; 138 (2): 522-530.
36. National Institute for Health Research. Chronic viral hepatitis in ethnic minorities. Strategies to prevent the predicted increase in mortality. 2012 [cited 2012 1/10/2012]; Available at: http://www.ccf.nihr.ac.uk/PGfAR/about/ Pages/FundedProgrammesOld.aspx. (accessed 7 May 2013).